Reed Elsevier has purchased Inpharmatica, a British bioinformatics firm. Before you conclude that Elsevier is diversifying, perhaps as a hedge against losses in STM publishing, consider how it is explaining the new purchase publicly. Excerpt from David Finn's story in today's Financial Times: 'Kevin Brown, partner in Reed Elsevier Ventures, said Inpharmatica's bioinformatics was one of the "disruptive technologies" that could revolutionise the life science publishing industry. "This is 21st century publishing. We see it as the next generation in harnessing all the public-domain information post the Human Genome Project with what the pharmaceutical industry has within its firewall and the software to harness it all," he said.'
Posted by
Peter Suber at 11/09/2004 05:16:00 PM.
The open access movement:
Putting peer-reviewed scientific and scholarly literature
on the internet. Making it available free of charge and
free of most copyright and licensing restrictions.
Removing the barriers to serious research.
